Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)

Annals of the Rheumatic Diseases

Volumn 75, Issue 9, 2016, Pages 1615-1621

  Franklyn, Kate ^a   Lau, Chak Sing ^b   Navarra, Sandra V ^c   Louthrenoo, Worawit ^d   Lateef, Aisha ^e   Hamijoyo, Laniyati ^f   Wahono, C Singgih ^g   Chen, Shun Le ^h   Jin, Ou ⁱ   Morton, Susan ^a   Hoi, Alberta ^a   Huq, Molla ^j   Nikpour, Mandana ^j   Morand, Eric F ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF SANTO TOMAS   (Philippines)

^d Chang Mai University   (Thailand)

^e NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^f PADJADJARAN UNIVERSITY   (Indonesia)

^g BRAWIJAYA UNIVERSITY   (Indonesia)

^h SHANGHAI JIAO TONG UNIVERSITY   (China)

ⁱ THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^j UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

Disease Activity; Outcomes research; Systemic Lupus Erythematosus

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE;

ADULT; ARTICLE; DELPHI STUDY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUPUS LOW DISEASE ACTIVITY STATE; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; ORGAN INJURY; PRIORITY JOURNAL; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; VALIDATION STUDY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; RISK; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME FACTOR;

ADULT; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; RISK; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84951816992     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-207726     Document Type: Article

References (28)

1. Mak A, Cheung MW, Chiew HJ, et al. Global trend of survival and damage of systemic lupus erythematosus: meta-analysis and meta-regression of observational studies from the 1950s to 2000s. Semin Arthritis Rheum 2012;41:830-9.
2. Alarcón GS, McGwin G Jr, Roseman JM, et al. Systemic lupus erythematosus in three ethnic groups. XIX. Natural history of the accrual of the American College of Rheumatology criteria prior to the occurrence of criteria diagnosis. Arthritis Rheum 2004;51:609-15.
3. Nossent J, Kiss E, Rozman B, et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 2010;19:949-56.
4. Alarcón GS, McGwin G Jr, Uribe A, et al. Systemic lupus erythematosus in a multiethnic lupus cohort (LUMINA). XVII. Predictors of self-reported health-related quality of life early in the disease course. Arthritis Rheum 2004;51:465-74.
5. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
6. Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005;44:902-6.
7. Verdecchia P, Staessen JA, Angeli F, et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009;374:525-33.
8. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9.
9. Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443-9.
10. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
11. Touma Z, Urowitz MB, Taghavi-Zadeh S, et al. Systemic lupus erythematosus disease activity Index 2000 Responder Index 50: sensitivity to response at 6 and 12 months. Rheumatology (Oxford) 2012;51:1814-19.
12. Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143-51.
13. Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 2014;73:183-90.
14. Steiman AJ, Urowitz MB, Ibañez D, et al. Prolonged clinical remission in patients with systemic lupus erythematosus. J Rheumatol 2014;41:1808-16.
15. Franklyn K, Hoi A, Nikpour M, et al. The need to define treatment goals for systemic lupus erythematosus. Nat Rev Rheumatol 2014;10:567-71.
16. van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014;73:958-67.
17. Gladman DD, Goldsmith CH, Urowitz MB, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol 2000;27:373-6.
18. Ibanez D, Gladman DD, Urowitz MB. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol 2005;32:824-7.
19. Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005;142(12 Pt 1):953-62.
20. Golder V, Connelly K, Staples M, et al. Association of Asian ethnicity with disease activity in SLE: an observational study from the Monash Lupus Clinic. Lupus 2013;22:1425-30.
21. Vincent F, Northcott M, Hoi A, et al. Clinical associations of serum interleukin-17 in systemic lupus erythematosus. Arthritis Res Ther 2013;15:R97.
22. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
23. Chambers SA, Allen E, Rahman A, et al. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford) 2009;48:673-5.
24. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91.
25. Felson D. Defining remission in rheumatoid arthritis. Ann Rheum Dis 2012;71 (Suppl 2):i86-8.
26. Zonana-Nacach A, Barr SG, Magder LS, et al. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000;43:1801-8.
27. Thamer M, Hernán MA, Zhang Y, et al. Prednisone, lupus activity, and permanent organ damage. J Rheumatol 2009;36:560-4.
28. Jolly M, Pickard AS, Block JA, et al. Disease-specific patient reported outcome tools for systemic lupus erythematosus. Semin Arthritis Rheum 2012;42:56-65.